Vanguard Group Inc. Boosts Position in Cellectar Biosciences, Inc. (NASDAQ:CLRB)

Vanguard Group Inc. boosted its holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 2.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 175,884 shares of the biopharmaceutical company’s stock after buying an additional 3,911 shares during the period. Vanguard Group Inc.’s holdings in Cellectar Biosciences were worth $464,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Renaissance Technologies LLC raised its holdings in Cellectar Biosciences by 11.5% in the second quarter. Renaissance Technologies LLC now owns 63,990 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 6,589 shares during the period. State Street Corp raised its holdings in Cellectar Biosciences by 4.5% in the second quarter. State Street Corp now owns 157,146 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 6,800 shares during the period. Citadel Advisors LLC purchased a new position in Cellectar Biosciences in the second quarter valued at approximately $60,000. Acuta Capital Partners LLC purchased a new position in Cellectar Biosciences in the third quarter valued at approximately $320,000. Finally, Worth Venture Partners LLC grew its position in Cellectar Biosciences by 122.8% in the first quarter. Worth Venture Partners LLC now owns 458,245 shares of the biopharmaceutical company’s stock valued at $315,000 after acquiring an additional 252,570 shares in the last quarter. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on CLRB shares. StockNews.com raised shares of Cellectar Biosciences to a “sell” rating in a research report on Thursday, March 28th. Roth Mkm increased their price objective on shares of Cellectar Biosciences from $20.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, Oppenheimer reissued an “outperform” rating and set a $12.00 price target (up previously from $11.00) on shares of Cellectar Biosciences in a research report on Thursday, March 28th.

Cellectar Biosciences Trading Down 5.4 %

CLRB stock opened at $3.32 on Tuesday. Cellectar Biosciences, Inc. has a twelve month low of $1.33 and a twelve month high of $4.45. The company has a market capitalization of $107.11 million, a P/E ratio of -1.07 and a beta of 0.92. The firm has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $3.09.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.